Results of the Phase II study CONFIDENCE demonstrate that simultaneous initiation of finerenone and an SGLT-2-inhibitor (SGLT-2i) led to significant reductions in urine albumin-to-creatinine ratio ...

Figure 1. DAZALS exploratory overall survival analysis at one-year – patients who received 300 mg of dazucorilant compared to ...

Casma’s first-in-class TRPML1 agonist represents a new therapeutic approach for targeting lysosomal dysfunction in genetically driven neurodegenerative diseases ...

Median overall survival (OS) from ateganosine (THIO) treatment extends to 17.8 months in latest data CHICAGO, IL, USA I June 05, 2025 I MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the ...

Company enters into option agreement with NeurOp to in-license novel GluN2B antagonists – Compounds include a highly potent and selective Phase 1-complete candidate and seven preclinical candidates – ...

SAN DIEGO, CA, USA I June 05, 2025 I Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology ...

LENSai™ powered by HYFT® technology Identifies a single multi-factorial target conserved across all dengue serotypes.

BOSTON, MY, USA I June 5, 2025 I Mediar Therapeutics, Inc., a clinical-stage biotechnology company advancing first-in-class therapies designed to halt fibrosis, today announced the first patient has ...

ROCKVILLE, MD, USA I June 5, 2025 I REGENXBIO Inc. (Nasdaq: RGNX) today announced new positive interim data from the Phase ...

Trial is expected to provide key insights on how paxalisib therapy can be combined with established immunotherapies and standard of care chemotherapy to ...

SOLANA BEACH, CA, USA I June 05, 2025 I Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling ...

HYDERABAD, India and REYKJAVIK, Iceland I June 05, 2025 I Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients ...